CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company’s Board of Directors, effective June 9, 2025. “It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology ...

Tivic Health Systems (TIVC) Conference June 11, 2025 01:30 PM ET Speaker0 Hello and welcome to Virtual Investor Conferences. On behalf of the Life Science Investor Forum and our co host, Zach SmallCap Research, we are very pleased you have joined us for our quarterly conference. Our next presentation is from Tivic. Please note, you may submit questions for the presenter in the box to the left of the slides. You can also view our company's availability for a one on one meeting by clicking book meeting in the ...

U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support licensureAdvisory Committee meeting scheduled for July 30, 2025Mid-cycle meeting recently completed with no significant issues or major deficiencies; late-cycle meeting planned for mid-JulyBiologics License Application remains under priority review with PDUFA target action date of August 31, 2025 SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnol ...

"Adial's collaboration with Cytel reinforces our commitment to disciplined capital deployment and data-driven execution," said Cary Claiborne, CEO at Adial. "By leveraging advanced analytics and adaptive design, we are in a strong position to generate meaningful clinical data while minimizing time and spend. We believe this strategy materially increases the probability of success for AD04 and creates significant value for patients and shareholders alike." Adial's platform is focused on developing geneticall ...

Group 1 - Castle Biosciences, Inc. will participate in a panel discussion at the 2025 BIO International Convention, focusing on the challenges faced by precision medicine companies in commercializing innovative diagnostic tests [1][2] - The panel titled "Advancing Innovative Risk-Stratification Tests That Impact Treatment Pathway Decisions: Challenges in Overcoming Barriers to Entry" is scheduled for June 17, 2025, from 11 a.m. to 12 p.m. Eastern Time [2] - The session will be moderated by Michael Ryan, J.D., and will include industry leaders discussing strategies for navigating market complexities while improving patient care [2][8] Group 2 - Castle Biosciences is a leading diagnostics company that aims to improve health through innovative tests that guide patient care [5] - The company's current portfolio includes tests for skin cancers, Barrett's esophagus, and uveal melanoma, with ongoing research for additional tests in high clinical need areas [6] - Castle Biosciences emphasizes a patient-first approach in transforming disease management, focusing on the needs of patients, clinicians, employees, and investors [5][6]

Core Insights - AbbVie is actively engaging with the administration regarding drug pricing policies and is optimistic about the productive nature of these discussions [3][4]. Group 1: Company Overview - AbbVie is represented by its entire management team at the Goldman Sachs 46th Annual Global Healthcare Conference [1]. - Robert A. Michael, CEO & Director, emphasizes the importance of addressing affordability and access to medicines while maintaining innovation [4]. Group 2: Industry Environment - The pharmaceutical sector is currently facing uncertainties related to drug pricing policies, particularly following the Most Favored Nation Executive Order [3]. - The administration's engagement with the pharmaceutical industry is seen as a positive development, indicating a willingness to discuss various topics related to drug pricing and access [4].

Core Insights - Philochem AG has entered into a definitive agreement with RayzeBio, granting exclusive worldwide rights to develop, manufacture, and commercialize OncoACP3, a therapeutic and diagnostic agent targeting prostate cancer [1][3] - The agreement includes a $350 million up-front payment and potential additional payments of up to $1.0 billion based on development, regulatory, and commercial milestones, along with mid-single to low double-digit royalties on global net sales [1][3] Company Overview - Philogen Group is a biotechnology company focused on developing pharmaceutical products for highly lethal diseases, utilizing proprietary technologies and a strong portfolio of patents [5] - The company aims to address high unmet medical needs, primarily in oncology, but also has potential applications in chronic inflammatory diseases [5] Product Details - OncoACP3 is a small molecule ligand with high affinity for Acid Phosphatase 3 (ACP3), currently undergoing evaluation in a Phase I trial, showing promising initial data with selective tumor uptake and minimal healthy tissue uptake [2] - IND-enabling activities are ongoing to support a Phase I therapeutic study with Ac-OncoACP3 [2] Strategic Importance - The collaboration with RayzeBio enhances Philochem's position in the radiopharmaceuticals space, aiming to deliver innovative treatments for prostate cancer [3] - This partnership reflects a shared commitment to translating scientific innovation into clinical solutions, potentially making OncoACP3 therapies widely available [3] Transaction Details - The closing of the transaction is subject to regulatory approvals and is expected to finalize in the third quarter of 2025 [4] - Philochem is advised by Centerview Partners UK LLP and Cooley LLP for this transaction [4]

Nautilus Biotechnology (NAUT) FY Conference June 10, 2025 02:00 PM ET Speaker0 You do, okay. Speaker1 question, I'll answer that. Speaker0 Oh, you're right. It does have that. Great. Good afternoon, everyone. I'm Matt Sykes, Life Science Tools and Diagnostics Analyst at Goldman Sachs. I have the pleasure of welcoming Anna Mari from Nautilus Biotechnologies. Thank you, Anna, for being here. Appreciate it. Maybe just starting off with big picture, can you give us kind of a brief overview of the proteomics mar ...

Amneal Pharmaceuticals (AMRX) FY Conference June 10, 2025 10:40 AM ET Speaker0 Okay. Great. Well, thank you everyone for joining us today. My name is Matt Delatorre, and I'm the generics pharma analyst here at GS. And we're we're very pleased to have Amneal Pharmaceuticals with us for this session with Sharag Patel, cofounder and co CEO, and Tassos Konidaris, the chief financial officer. Great. So maybe maybe just to get started, you know, how about just level set us on where Amneal is headed from kind of a ...

Ashvattha will present Phase 2 data on migaldendranib, a subcutaneous therapy for DME and wet AMD, which could offer a more patient-friendly alternative to current injection-based treatments Company is exploring new technology to normalize VEGF expression, potentially enhancing both safety and efficacy of treatments for retinal and other diseases REDWOOD CITY, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therap ...